PURP has been asked to participate in the University of Washington Addictions, Drug, & Alcohol Institute (ADAI) workgroup to help “tackle risks associated with high-THC products.” This organization wrote the consensus statement on Cannabis Concentration and Health Risks which was the basis of HB 1463, and lead research scientist Dr. Beatriz Carlini testified in support of the bill. Despite our current differences in perspective, we sincerely appreciate the fact that the ADAI reached out to PURP to participate in the conversation.
We encourage PURP members & supporters to read the ADAI's consensus statement on Cannabis Concentration and Health Risks, as well as their recent High THC concentration cannabis policy initial report and consider ways to prevent people (especially those aged 14-18) from experiencing the health risks associated with daily cannabis use, including Cannabis Hyperemesis Syndrome. We will begin presenting potential solutions for ADAI's consideration around February 18, 2022.
Their initial suggestions for policy changes tell you everything you need to know about their current understanding of cannabis use:
Cap THC concentration in products
Require a serving size for all products
Prohibit certain type of cannabis products
Limit total THC in a single purchase
Require a minimum CBD content
Restrict consumption by age
Regulate or prohibit marketing
Regulate packaging and labeling
Please read their consensus statement, their initial report, and use our contact form to submit suggestions that won’t contribute to the cannabis market becoming lamer than it already is.
Read our blog post on the ADAI workgroup to learn more about this project.